Literature DB >> 21859997

Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C.

Yen-Tsung Huang1, Chin-Lan Jen, Hwai-I Yang, Mei-Hsuan Lee, Jun Su, Sheng-Nan Lu, Uchenna H Iloeje, Chien-Jen Chen.   

Abstract

PURPOSE: Both hepatitis B (HBV) and C viruses (HCV) are causes of hepatocellular carcinoma (HCC), but lifetime risk and sex difference remain unclear. This study aimed to assess the lifetime risk and sex difference of HCC among patients with chronic HBV and/or HCV.
METHODS: A prospective cohort of 23,820 residents of Taiwan age 30 to 65 years were enrolled from 1991 to 1992, with 477 instances of HCC occurring subsequently. Serum samples collected at enrollment were tested for seromarkers and viral load of HBV and HCV. Newly developed HCC was ascertained through computerized data linkage with national cancer registry and death certification systems.
RESULTS: The cumulative lifetime (age 30 to 75 years) incidences of HCC for men and women positive for both HBV surface antigen (HBsAg) and antibodies against HCV (anti-HCV) were 38.35% and 27.40%; for those positive for HBsAg only, 27.38% and 7.99%; for those positive for anti-HCV only, 23.73% and 16.71%; and for those positive for neither, 1.55% and 1.03%, respectively. There was a significant male predominance in incidence of HCC for chronic HBV carriers but not for chronic carriers of HCV or both. Multivariate adjusted hazard ratio of developing HCC decreased with age in HBsAg-seropositive men but increased with age in anti-HCV-seropositive women. Among dual-infected participants, there was an inverse association between HBV and HCV viral load. Risk of HCC increased significantly with increasing viral load of HBV and HCV.
CONCLUSION: There exists a suppressive effect of HCV on HBV viral load. Individual and combined effects of the two viruses on HCC vary with sex and age.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21859997      PMCID: PMC4874144          DOI: 10.1200/JCO.2011.36.2335

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  42 in total

1.  Nosocomial transmission of HCV in the liver unit of a tertiary care center.

Authors:  Xavier Forns; Eva Martínez-Bauer; Anna Feliu; Montserrat García-Retortillo; Marta Martín; Eugeni Gay; Miquel Navasa; Jose Maria Sánchez-Tapias; Miquel Bruguera; Juan Rodés
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

2.  Hepatitis viruses.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risks Hum       Date:  1994

3.  Prevalence and manifestations of hepatitis C seropositivity in children in an endemic area.

Authors:  S N Lu; H C Chen; C M Tang; M H Wu; M L Yu; W L Chuang; C F Lu; W Y Chang; C J Chen
Journal:  Pediatr Infect Dis J       Date:  1998-02       Impact factor: 2.129

4.  A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma.

Authors:  F Donato; P Boffetta; M Puoti
Journal:  Int J Cancer       Date:  1998-01-30       Impact factor: 7.396

5.  Epidemiology of hepatitis B virus infection in the Asia-Pacific region.

Authors:  C J Chen; L Y Wang; M W Yu
Journal:  J Gastroenterol Hepatol       Date:  2000-05       Impact factor: 4.029

6.  The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age.

Authors:  M H Chang; H Y Hsu; H C Hsu; Y H Ni; J S Chen; D S Chen
Journal:  Hepatology       Date:  1995-11       Impact factor: 17.425

7.  Dominant replication of either virus in dual infection with hepatitis viruses B and C.

Authors:  K Koike; K Yasuda; H Yotsuyanagi; K Moriya; K Hino; K Kurokawa; S Iino
Journal:  J Med Virol       Date:  1995-02       Impact factor: 2.327

8.  A nested case-control study on association between hepatitis C virus antibodies and primary liver cancer in a cohort of 9,775 men in Taiwan.

Authors:  C C Chang; M W Yu; C F Lu; C S Yang; C J Chen
Journal:  J Med Virol       Date:  1994-07       Impact factor: 2.327

Review 9.  Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis.

Authors:  M Anzola
Journal:  J Viral Hepat       Date:  2004-09       Impact factor: 3.728

10.  A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China.

Authors:  J Shi; L Zhu; S Liu; W-F Xie
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

View more
  53 in total

1.  Hospital stays for hepatitis B or C virus infection or primary liver cancer among immigrants: a census-linked population-based cohort study.

Authors:  Edward Ng; Robert P Myers; Doug Manuel; Claudia Sanmartin
Journal:  CMAJ Open       Date:  2016-04-28

Review 2.  Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection.

Authors:  Chun-Jen Liu; Pei-Jer Chen
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

3.  Differences in the prognostic value of tumor size on hepatocellular cancer-specific survival stratified by gender in a SEER population-based study.

Authors:  Wenjie Zhang; Kangpeng Jin; Fei Wang; Guangyan Zhangyuan; Weiwei Yu; Yang Liu; Haitian Zhang; Ping Zhang; Beicheng Sun
Journal:  United European Gastroenterol J       Date:  2019-04-24       Impact factor: 4.623

Review 4.  Impact of etiological treatment on prognosis.

Authors:  Chien-Wei Su; Ying-Ying Yang; Han-Chieh Lin
Journal:  Hepatol Int       Date:  2017-07-12       Impact factor: 6.047

5.  Does the Sex-Determining Region on the Y Chromosome (SRY) Correlate with Gender Disparity in Liver Disease?

Authors:  Xu-Feng Zhang; Yi Lv
Journal:  Dig Dis Sci       Date:  2015-02-10       Impact factor: 3.199

6.  Hepatocellular carcinoma risk scores: ready to use in 2015?

Authors:  Chien-Jen Chen; Mei-Hsuan Lee; Jessica Liu; Hwai-I Yang
Journal:  Hepat Oncol       Date:  2015-01-12

7.  Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection.

Authors:  Huei-Ru Cheng; Jia-Horng Kao; Hui-Lin Wu; Tai-Chung Tseng; Chen-Hua Liu; Hung-Chih Yang; Tung-Hung Su; Pei-Jer Chen; Ding-Shinn Chen; Chun-Jen Liu
Journal:  Hepatol Int       Date:  2014-11-18       Impact factor: 6.047

Review 8.  Hepatocellular Carcinoma: Etiology and Current and Future Drugs.

Authors:  Aastha Jindal; Anusha Thadi; Kunwar Shailubhai
Journal:  J Clin Exp Hepatol       Date:  2019-01-25

Review 9.  Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.

Authors:  Wen-Lung Ma; Hsueh-Chou Lai; Shuyuan Yeh; Xiujun Cai; Chawnshang Chang
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

10.  Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk.

Authors:  Yan Du; Xue Han; Rui Pu; Jiaxin Xie; Yuwei Zhang; Guangwen Cao
Journal:  Front Med       Date:  2014-04-21       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.